Staphylokinase
- Generic Name
- Staphylokinase
- Indication
适用于成人由冠状动脉血栓引起的急性心肌梗塞溶栓治疗。本品应在症状发生后，尽可能早期使用。
Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry)
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Supergene, LLC
- Target Recruit Count
- 23250
- Registration Number
- NCT06707987
- Locations
- 🇷🇺
Federal Brain and Neurotechnology Center, Moscow, Russian Federation
Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism
- Conditions
- Pulmonary Embolism
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Supergene, LLC
- Target Recruit Count
- 486
- Registration Number
- NCT06362746
- Locations
- 🇷🇺
Asinovskaya District Hospital, Asino, Tomsk Region, Russian Federation
🇷🇺N.A. Semashko Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod, Russian Federation
🇷🇺V.F. Dolgopolov Vyselki Central District Hospital, Vyselki, Krasnodar Region, Russian Federation
Prolonged Clinical Follow-up of OPTIMA-5
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI)
- Interventions
- Drug: Normal Saline
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-02-26
- Target Recruit Count
- 210
- Registration Number
- NCT05649696
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳Changzhou Second People's Hospital, Changzhou, China
🇨🇳The second Affiliated Hospital of Dalian Medical University, Dalian, China
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
- Conditions
- ST Elevation Myocardial Infarction
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2024-10-28
- Target Recruit Count
- 2260
- Registration Number
- NCT05410925
- Locations
- 🇨🇳
Huai'an Second People's Hospital, Huai'an, China
🇨🇳The First People's Hospital of Lianyungang, Lianyungang, China
🇨🇳The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China
Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial
- Conditions
- Acute Limb Ischemia
- Interventions
- Procedure: surgical methods of treatment
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Supergene, LLC
- Target Recruit Count
- 170
- Registration Number
- NCT05372718
- Locations
- 🇷🇺
Sergiyev Posad Regional Clinical Hospital, Sergiyev Posad, Moscow Region, Russian Federation
🇷🇺Kazan State Medical University, Kazan, Republic Of Tatarstan, Russian Federation
🇷🇺S.S. Yudin City clinical hospital, Moscow, Russian Federation
Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial
- Conditions
- COVID-19
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Supergene, LLC
- Target Recruit Count
- 4
- Registration Number
- NCT05135546
- Locations
- 🇷🇺
City Clinical Hospital No.52, Moscow, Russian Federation
🇷🇺N.V. Sklifosovsky Research Institute of Emergency Medicine, Moscow, Russian Federation
The OPTIMA-5 Trail
- Conditions
- Acute Myocardial Infarction
- Interventions
- Drug: normal saline
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2023-01-13
- Target Recruit Count
- 200
- Registration Number
- NCT05023681
- Locations
- 🇨🇳
The second Affiliated Hospital of Dalian Medical University, Dalian, China
🇨🇳Taizhou People's Hospital, Taizhou, China
🇨🇳The Second Affiliated Hospital of Zhejiang University Medical College, Hangzhou, China
Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE
- Conditions
- Massive Pulmonary Embolism
- Interventions
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Supergene, LLC
- Target Recruit Count
- 310
- Registration Number
- NCT04688320
- Locations
- 🇷🇺
Sergiyev Posad Regional Clinical Hospital, Sergiyev Posad, Moscow Region, Russian Federation
🇷🇺V.F. Dolgopolov Vyselki Central District Hospital, Vyselki, Krasnodar Region, Russian Federation
🇷🇺Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk, Russian Federation
Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS
- Conditions
- Ischemic Stroke
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Supergene, LLC
- Target Recruit Count
- 336
- Registration Number
- NCT03151993
- Locations
- 🇷🇺
City Clinical Hospital №11, Ryazan', Russian Federation
🇷🇺Regional Clinical Hospital, Ulyanovsk, Russian Federation
🇷🇺Regional Clinical Hospital №1, Voronezh, Russian Federation
Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI
- Conditions
- Myocardial Infarction
- Interventions
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Supergene, LLC
- Target Recruit Count
- 382
- Registration Number
- NCT02301910
- Locations
- 🇷🇺
Regional Clinical Hospital, Tver, Russian Federation
🇷🇺Institute of Cardiology, Tomsk, Siberia, Russian Federation
🇷🇺St. Iosaf's Belgorod Regional Clinical Hospital, Belgorod, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.